Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin in Recurrent or Persistent Endometrial Carcinoma
NCT00071929Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Nov 1999
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in endometrial carcinoma, sponsored by GOG Foundation. Primary endpoint: Objective Response Rate. Started Nov 1999; status: completed.
02
Drugs
oxaliplatin
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00071929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071929.